Domain I of beta 2GPI is capable of blocking serum IgA antiphospholipid antibodies binding in vitro: an effect enhanced by PEGylation

Albay A., Artim-Esen B., PERICLEOUS C., Wincup C., Giles I., Rahman A., ...Daha Fazla

LUPUS, cilt.28, sa.7, ss.893-897, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 28 Sayı: 7
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1177/0961203319851571
  • Dergi Adı: LUPUS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.893-897
  • İstanbul Üniversitesi Adresli: Evet

Özet

Objectives This study aims to inhibit antiphospholipid syndrome (APS) serum derived IgA anti-beta-2-glycoprotein I (a beta 2GPI) binding using Domain I (DI). Methods Serum from 13 APS patients was tested for IgA a beta 2GPI and Anti-Domain I. Whole IgA was purified by peptide M affinity chromatography from positive serum samples. Serum was tested for IgA a beta 2GPI binding in the presence and absence of either DI or of two biochemically modified variants containing either 20 kDa of poly(ethylene glycol) (PEG) or 40 kDa of PEG. Results Significant inhibition with DI was possible with average inhibition of 23% (N = 13). Further inhibitions using 20 kDa PEG-DI and 40 kDa PEG-DI variants showed significant inhibition (p = 0.0001) with both the 40 kDa PEG-DI and 20 kDa PEG-DI variants showing increased inhibition compared with DI alone (p = 0.0001 and p = 0.001, n = 10). Conclusions Inhibition of IgA a beta 2GPI by DI is possible and can be enhanced by biochemical modification in a subset of patients.